



Biosergen publishes interim report for third quarter 2023

Thursday, November 30, 2023: Biosergen AB ("Biosergen" or the "Company") hereby publishes the interim report for the third quarter 2023. The interim report is available as an attached document and on the company website (www.biosergen.net)

Summary of the Interim Report for Q3 2023

TSEK	2023 July-Sep	2022 July-Sep	2023 Jan-Sept	2022 Jan-Sep	2022 Jan-Dec
Profit/loss					
Other income	292	493	8.063	3.219	5.183
Profit/loss before depreciation (EBITDA)	-7.537	-14.515	-20.604	-27.496	-34.129
Operating profit/loss before net financials	-7.537	-14.515	-20.604	-27.496	-34.129
Net financials	27	16	36	22	81
Netprofit/loss for the period	-7.510	-14.499	-20.568	-27.474	-34.048
Earnings per share (SEK)	-0,15	-0,51	-0,48	-0,97	-1,09

Highlights during Q3 2023

- September 25, Biosergen and Alkem Laboratories Ltd collaborates to develop anti-infective for severe fungal infections.
- August 28, Warrants series TO2 were exercised to approximately 96.1 percent and Biosergen AB receives approximately SEK 5.5 million.
- August 16, Biosergen Receives Full Subscription Guarantees for Warrant Exercise from Largest Shareholders and Executive Management.
- August 7, Biosergen Announces Abstract Accepted for Presentation at the 11th Congress on Trends in Medical Mycology (TIMM-11).

Highlights after the period

- Abstract presented at the 11th Trends in Medical Mycology publicly available

The Financial report can be found on our website: <http://biosergen.net/investors/filings>

For further information about Biosergen, please contact:

Dr. Peder M. Andersen, CEO

Telephone: +45 2080 2470

E-mail: peder.andersen@biosergen.net

Niels Laursen, CFO

Telephone: +45 4014 5059

Email: niels.laursen@biosergen.net

The Company's Certified Adviser is Carnegie Investment Bank AB (publ).

ABOUT BIOSERGEN

Biosergen is a leading clinical-stage biotechnology company at the forefront of antifungal drug development. Our mission is to develop BSG005, our lead drug candidate, into the new first-line treatment choice for invasive fungal diseases, while generating significant returns for our shareholders. Our Phase I trial showcased the exceptional safety and tolerability of BSG005, especially when compared to existing alternatives. Building on those results we are now advancing to test the drug in patients expected to clinically validate BSG005's potential as a new and strong antifungal treatment. Biosergen's development of BSG005 is based on two decades of scientific work at the Norwegian University of Science and Technology. For more information, visit www.biosergen.net.